CO6680689A2 - Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina - Google Patents

Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina

Info

Publication number
CO6680689A2
CO6680689A2 CO13041062A CO13041062A CO6680689A2 CO 6680689 A2 CO6680689 A2 CO 6680689A2 CO 13041062 A CO13041062 A CO 13041062A CO 13041062 A CO13041062 A CO 13041062A CO 6680689 A2 CO6680689 A2 CO 6680689A2
Authority
CO
Colombia
Prior art keywords
pains
bradykinin
receptor antagonists
compounds substituted
well
Prior art date
Application number
CO13041062A
Other languages
English (en)
Inventor
Norbert Hauel
Angelo Ceci
Henri Doods
Birgit Jung
Raimund Kuelzer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CO6680689A2 publication Critical patent/CO6680689A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

La presente invención se refiere a compuestos de tetrahidrofuranilo disustituidos de la Fórmula general I:Así como a sus enantiómeros, sus diastereoisómeros, sus mezclas y sus sales, en especial aquellas sales fisiológicamente aceptables con ácidos o bases orgánicos o inorgánicos, que poseen propiedades analgésicas, un procedimiento para su fabricación, composiciones que los contienen y que son adecuados para su uso en la profilaxis o el tratamiento de dolores agudos, dolores viscerales, dolores neuropáticos, dolores inflamatorios y dolores mediados por receptores del dolor, dolores tumorales, así como dolores de cabeza.
CO13041062A 2010-08-20 2013-02-28 Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina CO6680689A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10173489 2010-08-20

Publications (1)

Publication Number Publication Date
CO6680689A2 true CO6680689A2 (es) 2013-05-31

Family

ID=44510978

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13041062A CO6680689A2 (es) 2010-08-20 2013-02-28 Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina

Country Status (36)

Country Link
US (1) US8937073B2 (es)
EP (1) EP2606042B1 (es)
JP (1) JP5727011B2 (es)
KR (1) KR101822371B1 (es)
CN (1) CN103068817B (es)
AP (1) AP2012006630A0 (es)
AR (1) AR082507A1 (es)
AU (1) AU2011290727B2 (es)
BR (1) BR112013003752A2 (es)
CA (1) CA2807086A1 (es)
CL (1) CL2013000310A1 (es)
CO (1) CO6680689A2 (es)
CY (1) CY1115933T1 (es)
DK (1) DK2606042T3 (es)
EA (1) EA022787B1 (es)
EC (1) ECSP13012495A (es)
ES (1) ES2525296T3 (es)
GE (1) GEP20146196B (es)
HK (1) HK1178902A1 (es)
HR (1) HRP20141172T1 (es)
IL (1) IL224039A (es)
MA (1) MA34578B1 (es)
ME (1) ME01899B (es)
MX (1) MX352548B (es)
MY (1) MY156233A (es)
NZ (1) NZ607435A (es)
PE (1) PE20130810A1 (es)
PL (1) PL2606042T3 (es)
PT (1) PT2606042E (es)
RS (1) RS53622B1 (es)
SG (1) SG187835A1 (es)
SI (1) SI2606042T1 (es)
TW (1) TWI548632B (es)
UA (1) UA108765C2 (es)
UY (1) UY33565A (es)
WO (1) WO2012022795A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007034620A1 (de) * 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
EP2188254B1 (de) 2007-08-29 2012-03-21 Boehringer Ingelheim International GmbH Neue bradykinin b1-antagonisten
US8937073B2 (en) 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US20180221365A1 (en) * 2015-05-12 2018-08-09 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
US11401303B2 (en) * 2020-06-15 2022-08-02 Taian City Qihang Biotechnology Co. Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI259079B (en) 2002-02-08 2006-08-01 Merck & Co Inc N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives
ATE316954T1 (de) * 2002-02-08 2006-02-15 Merck & Co Inc N-biphenylmethylaminocycloalkancarboxamid- derivative
US7163951B2 (en) 2002-08-29 2007-01-16 Merck & Co., Inc. N-biarylmethyl aminocycloalkanecarboxamide derivatives
CA2534188A1 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides
CN1832922A (zh) * 2003-08-07 2006-09-13 默克公司 磺酰基取代的n－(联芳基甲基)氨基环丙烷甲酰胺类
JP2007526311A (ja) * 2004-03-02 2007-09-13 メルク　エンド　カムパニー　インコーポレーテッド ブラジキニンアンタゴニストとしてのアミノシクロプロパンカルボキサミド誘導体
US20060173023A1 (en) 2005-02-01 2006-08-03 Wood Michael R 2-(Bicyclo)alkylamino-derivatives as mediators of chronic pain and inflammation
WO2008033564A1 (en) * 2006-09-15 2008-03-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
HUP0600809A3 (en) * 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
DE102007034620A1 (de) 2007-07-25 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue B1-Antagonisten
EP2025675A1 (de) 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamide mit analgetischer Wirkung
EP2188254B1 (de) 2007-08-29 2012-03-21 Boehringer Ingelheim International GmbH Neue bradykinin b1-antagonisten
AR068509A1 (es) 2007-09-19 2009-11-18 Jerini Ag Antagosnistas del receptor de bradiquinina b1
WO2010057899A1 (de) 2008-11-20 2010-05-27 Boehringer Ingelheim International Gmbh Cykloalkylaminocarbonylderivate als bradykinin-b1-rezeptor antagonisten
WO2010097374A1 (de) 2009-02-26 2010-09-02 Boehringer Ingelheim International Gmbh Verbindungen als bradykinin-b1-antagonisten
BRPI1008779A2 (pt) 2009-02-26 2020-12-22 Boehringer Ingelheim International Gmbh. Compostos como antagonistas de bradiquinina-b1
KR101843341B1 (ko) 2010-02-23 2018-03-30 베링거 인겔하임 인터내셔날 게엠베하 브라디키닌 ｂ１ 길항제로서의 화합물
JP5934212B2 (ja) 2010-08-20 2016-06-15 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 複数のプロスタグランジン受容体に作用し、一般的な抗炎症反応を生じる化合物
US8937073B2 (en) 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
US8901127B2 (en) 2010-08-20 2014-12-02 Boehringer Ingelheim International Gmbh Pyridazin derivatives as antagonists of the bradykinin B1 receptor
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1

Also Published As

Publication number Publication date
AR082507A1 (es) 2012-12-12
UY33565A (es) 2012-03-30
RS53622B1 (en) 2015-04-30
EA022787B1 (ru) 2016-03-31
EP2606042B1 (de) 2014-09-03
PE20130810A1 (es) 2013-07-25
KR101822371B1 (ko) 2018-01-31
PL2606042T3 (pl) 2015-03-31
MX2013001965A (es) 2013-05-09
NZ607435A (en) 2015-07-31
AU2011290727A1 (en) 2013-03-14
HK1178902A1 (en) 2013-09-19
WO2012022795A1 (de) 2012-02-23
MY156233A (en) 2016-01-29
IL224039A (en) 2016-03-31
CN103068817B (zh) 2014-10-29
EA201201662A1 (ru) 2013-07-30
ES2525296T3 (es) 2014-12-19
SI2606042T1 (sl) 2014-12-31
ME01899B (me) 2014-12-20
PT2606042E (pt) 2014-10-15
HRP20141172T1 (hr) 2015-02-13
TWI548632B (zh) 2016-09-11
KR20130114082A (ko) 2013-10-16
DK2606042T3 (da) 2014-12-08
US20120208823A1 (en) 2012-08-16
BR112013003752A2 (pt) 2016-05-31
ECSP13012495A (es) 2013-04-30
CA2807086A1 (en) 2012-02-23
JP2013534238A (ja) 2013-09-02
GEP20146196B (en) 2014-11-10
UA108765C2 (xx) 2015-06-10
AP2012006630A0 (en) 2012-12-31
CL2013000310A1 (es) 2013-04-01
AU2011290727B2 (en) 2015-07-16
EP2606042A1 (de) 2013-06-26
CY1115933T1 (el) 2017-01-25
US8937073B2 (en) 2015-01-20
MA34578B1 (fr) 2013-10-02
TW201305145A (zh) 2013-02-01
CN103068817A (zh) 2013-04-24
JP5727011B2 (ja) 2015-06-03
MX352548B (es) 2017-11-29
SG187835A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
CO6680689A2 (es) Compuestos de tetrahidrofuranilo disustituidos como antagonistas del receptor b1 de bradiquinina
DOP2018000257A (es) Piridinas sustituidas con heteroarilo y métodos de uso
CO2020011908A2 (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a/a2b
CO2018011550A2 (es) Compuestos de pirrolotriazina como inhibidores de tam
CR20190301A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
CU20110052A7 (es) Compuestos orgánicos
SV2018005663A (es) Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer
CU24335B1 (es) Piridopirimidinas sustituidas como inhibidores de la quinasa mek y útiles para el tratamiento del cáncer
CY1116958T1 (el) Υποκατεστημενες τριαζολοπυριδινες και η χρηση τους ως ττκ αναστολεις
CO7400867A2 (es) Modificador del sabor dulce
CU24605B1 (es) Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
DOP2018000115A (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
PA8848201A1 (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
CU24410B1 (es) Benzimidazol-2-aminas como inhibidores de midh1
CO7240375A2 (es) Compuestos tricíclicos sustituidos como inhibidores del fgfr
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
DOP2017000066A (es) Compuestos y composiciones como inhibidores de quinasa raf
CU20110145A7 (es) Derivados de sulfonamida
CO6630147A2 (es) Modificador del sabor dulce
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
CU20160157A7 (es) Derivados de diheterociclo enlazado a cicloalquilo
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
AR089929A1 (es) Proceso para manufacturar un derivado de naftiridina

Legal Events

Date Code Title Description
FG Application granted